Retatrutide is the first triple GIP/GLP-1/glucagon receptor agonist in clinical trials. For type 2 diabetes, the glucagon receptor component adds direct hepatic glucose suppression — a mechanism not present in tirzepatide or semaglutide — on top of the insulin secretion and sensitization effects of GLP-1/GIP agonism. Phase 2 data showed HbA1c reductions of ~2.0% at the 12 mg dose with the greatest weight loss of any agent (~24.2% at 48 weeks).
In type 2 diabetes, three core defects drive hyperglycemia: insufficient insulin secretion, peripheral insulin resistance, and excessive hepatic glucose production driven by glucagon excess. Retatrutide's triple mechanism addresses all three simultaneously — GLP-1/GIP agonism corrects insulin secretion and sensitivity, while glucagon receptor agonism directly suppresses the hepatic glucose output that drives fasting hyperglycemia.
GLP-1 agonism enhances glucose-dependent insulin secretion and suppresses glucagon. GIP agonism adds peripheral insulin sensitization. Glucagon receptor agonism suppresses hepatic glucose output — a unique mechanism not present in semaglutide or tirzepatide that directly addresses one of the key drivers of fasting hyperglycemia in T2D.
The glucagon receptor component directly suppresses hepatic glucose production, which is elevated in T2D due to glucagon excess. This hepatic effect is additive to the insulin secretion and sensitization effects of GLP-1 and GIP agonism, potentially producing a more complete correction of fasting hyperglycemia.
Retatrutide produced ~24.2% weight loss at 48 weeks in Phase 2 — the greatest of any agent. For T2D patients, this degree of weight loss produces substantial improvements in insulin resistance that go beyond the direct pharmacological effects, potentially enabling dose reduction or discontinuation of other diabetes medications.
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
The following data is derived from Phase 2 trials. HbA1c estimates are extrapolated from the obesity Phase 2 trial which included patients with T2D as a subgroup. Dedicated T2D Phase 3 trial data will supersede these estimates upon completion.
| Dose | Est. HbA1c Reduction | Weight Loss | Nausea Rate |
|---|---|---|---|
| 1 mg | ~−0.8% | −7.9% | ~20% |
| 2 mg | ~−1.1% | −12.9% | ~25% |
| 4 mg | ~−1.4% | −17.3% | ~30% |
| 8 mg | ~−1.8% | −22.8% | ~35% |
| 12 mg | ~−2.0% | −24.2% | ~40% |
HbA1c estimates are extrapolated from Phase 2 obesity trial T2D subgroup data. Phase 3 dedicated diabetes trial data pending.
| Metric | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Mechanism | GIP + GLP-1 + Glucagon | GIP + GLP-1 | GLP-1 |
| HbA1c reduction (max) | ~−2.0% (Phase 2) | −2.4% (SURPASS-2) | −1.9% (SUSTAIN-7) |
| Weight loss (max) | −24.2% (48 wks, Ph2) | −22.5% (72 wks) | −14.9% (68 wks) |
| Hepatic glucose | Direct suppression | Indirect (via insulin) | Indirect (via insulin) |
| GI side effects | More pronounced | Moderate | Moderate |
| FDA approval | No (Phase 3 ongoing) | Yes (Mounjaro, 2022) | Yes (Ozempic, 2017) |
| Long-term safety | Limited (Phase 2 only) | Growing (SURPASS) | Extensive (SUSTAIN) |
| Timepoint | Tests & Assessments |
|---|---|
| Baseline | HbA1c, FPG, eGFR, LFTs, lipid panel, weight, BP, glucagon levels if available |
| Week 4 | FPG, GI tolerance check, hydration assessment |
| Week 12 | HbA1c, FPG, weight, BP, eGFR, dose escalation decision |
| Week 24 | HbA1c, FPG, weight, lipid panel, eGFR, LFTs |
| Week 40–48 | Full panel: HbA1c, FPG, eGFR, LFTs, lipid panel, weight, BP, eye exam |
| Every 6 mos | HbA1c, FPG, weight, BP, eGFR (maintenance) |
No. Retatrutide is not yet FDA-approved for any indication. It completed Phase 2 trials for obesity and type 2 diabetes with impressive results and is currently in Phase 3 trials. The Phase 2 diabetes data showed HbA1c reductions of 1.5–2.0% at the 8–12 mg doses, comparable to tirzepatide. FDA approval is expected in 2025–2026 pending Phase 3 results.
Phase 2 data showed retatrutide reduced HbA1c by approximately 1.5–2.0% at the 8 mg and 12 mg doses in patients with T2D. The glucagon receptor component adds a unique hepatic glucose output suppression effect not present in semaglutide or tirzepatide, which may contribute to the glycemic benefit beyond GLP-1/GIP agonism alone.
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. For diabetes: GLP-1 agonism enhances glucose-dependent insulin secretion and suppresses glucagon; GIP agonism adds insulin sensitization and additional insulin secretion; glucagon receptor agonism suppresses hepatic glucose output and promotes fat oxidation. The triple mechanism produces a more complete glycemic correction than dual or single agonists.
Based on Phase 2 data, retatrutide's glycemic efficacy is comparable to tirzepatide. The glucagon component adds hepatic glucose suppression that tirzepatide lacks, but also increases GI side effects. The key differentiator is the greater weight loss with retatrutide (~24% vs ~22.5% for tirzepatide), which has secondary benefits for insulin resistance. However, retatrutide is not yet approved and has less long-term safety data.
Like tirzepatide and semaglutide, retatrutide stimulates insulin secretion in a glucose-dependent manner, giving it a low intrinsic hypoglycemia risk as monotherapy. However, the glucagon receptor agonism adds a layer of complexity — glucagon normally raises blood glucose, so blocking it could theoretically increase hypoglycemia risk in certain contexts. Phase 2 data showed low hypoglycemia rates similar to other GLP-1 class agents.
Based on Phase 2 protocols, retatrutide titrates from 0.5 mg/week up to 8–12 mg/week over 20 weeks. The 8 mg and 12 mg doses showed the greatest glycemic benefit. Phase 3 diabetes-specific trials may establish different dosing protocols. Final approved dosing will be determined upon FDA review.
The most common side effects are GI-related: nausea (30–40%), vomiting (15–20%), diarrhea (15–20%), and decreased appetite. The GI burden is more pronounced than tirzepatide, likely due to the glucagon receptor component. For diabetes patients, the weight loss and appetite suppression effects are generally beneficial. Monitoring for dehydration and renal function is important, especially in elderly patients.
For patients with T2D who retain significant beta cell function, retatrutide's triple mechanism may achieve glycemic targets without insulin. The greater weight loss vs tirzepatide and semaglutide may produce more substantial improvements in insulin resistance. However, Phase 3 insulin-comparison trials have not yet been completed. Patients with advanced T2D and beta cell failure still require insulin.
Third-party COA verified, ≥99% purity. Ships same day.
Shop Purgo LabsSemaglutide for type 2 diabetes: HbA1c reduction, cardiovascular outcomes, and dosage protocols.
Tirzepatide for type 2 diabetes: SURPASS trial HbA1c reduction and cardiovascular outcomes.
Complete retatrutide research guide: triple agonist mechanism, TRIUMPH trial results, dosage protocols, and comparison to semaglutide.